Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Trump officials reject Medicare coverage ...

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access ...

Maxeon Solar Technologies said it is establishing an alternative network of supply-chain partners and increasing its manufacturing capabilities in the U.S. as it deals with new tariffs and trade ...

Trump administration rejects a Biden plan to expand Medicare coverage of weight-loss drugs such as Zepbound and Wegovy.

The Centers for Medicare & Medicaid Services said on Friday it did not move forward with a proposal put forth by the Biden ...

The Biden administration proposal would have significantly expanded access to obesity to millions of Americans but would have cost the government billions.

Extending coverage for the medications through Medicare could cost $35 billion over nine years, a congressional analysis ...

Eli Lilly’s stock fell by 2.3% to close at 4:35 PM ET in after-hours trading, while Novo Nordisk’s American depositary receipts saw a decrease of 1.7%. This development came as a surprise to investors ...

Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

With two new lawsuits, Eli Lilly (NYSE: LLY) has escalated its legal campaign against the makers of unauthorized versions of ...